Business Update
Symbollon gets U.S. FDA regulatory guidance for developing upper respiratory tract drug
Published in Respiratory Therapeutics Week, September 4th, 2006
After discussions with the U.S. Food and Drug Administration (FDA), the company is planning to conduct a 30-day repeat dose animal study prior to filing an investigational new drug (IND) application in 2007.
Nasodine is a proprietary formulation designed to eliminate drug-resistant Staphylococcus aureus in the nasal cavity.
Part of Symbollon's business strategy is to develop a family of safe, broad-spectrum antimicrobial...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Respiratory Therapeutics Week
More Articles from Respiratory Therapeutics Week
- Emergency Medicine
Percutaneous transtracheal ventilation during respiratory arrest successful - Lung Cancer
Lung tumor radiotherapy planning via 4DCT minimizes risk of normal tissue toxicity - Non-Small Cell Lung Cancer
Avastin filed in Europe for treatment of most common form of lung cancer - Respiratory Medicine
Respiratory syncytial virus-related lower respiratory tract infections higher in preterm infants - Airway Viral Infection
Antiviral defense impaired in epithelial nitric oxide-deficient patients - Allergy & Immunology
Sinonasal endoscopy is a painless way to relieve sinusitis symptoms - More from this issue of Respiratory Therapeutics Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
